Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis
Completed
Pfizer
2013-07-26
The objective of this Surveillance is to verify the following subject matters concerning
Tofacitinib (Xeljanz) under general practice.
1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy
2） Long-term safety (particularly, malignant tumors and serious infections) and efficacy
Occurrences of malignant tumors and serious infections will be compared with a control group.
Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
Completed
Locks of Love
Phase 2
2015-01-01
This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of
moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up
off drug to assess the incidence and timing of recurrence of disease or documentation of
delayed response to treatment. There will be the option of increasing the treatment duration
up to an additional 6 months beyond the initially scheduled 6 months of treatment, if
clinically indicated, and at the discretion of the investigator.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
